CN103012410A - 一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 - Google Patents
一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 Download PDFInfo
- Publication number
- CN103012410A CN103012410A CN2012105639760A CN201210563976A CN103012410A CN 103012410 A CN103012410 A CN 103012410A CN 2012105639760 A CN2012105639760 A CN 2012105639760A CN 201210563976 A CN201210563976 A CN 201210563976A CN 103012410 A CN103012410 A CN 103012410A
- Authority
- CN
- China
- Prior art keywords
- tetrazine
- equal
- compound
- triazole
- triazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical compound C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 title abstract 5
- 238000009795 derivation Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000006467 substitution reaction Methods 0.000 claims abstract description 27
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 150000003852 triazoles Chemical class 0.000 claims description 97
- 239000002904 solvent Substances 0.000 claims description 53
- -1 tetrazine derivative compound Chemical class 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- 238000001953 recrystallisation Methods 0.000 claims description 18
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000004210 ether based solvent Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 132
- 238000006243 chemical reaction Methods 0.000 description 49
- 239000000047 product Substances 0.000 description 32
- 238000010792 warming Methods 0.000 description 21
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 20
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 238000013019 agitation Methods 0.000 description 15
- 238000004821 distillation Methods 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 15
- 229910052697 platinum Inorganic materials 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000000967 suction filtration Methods 0.000 description 15
- 229960000935 dehydrated alcohol Drugs 0.000 description 13
- 150000004905 tetrazines Chemical class 0.000 description 13
- 230000000452 restraining effect Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 238000010583 slow cooling Methods 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229960003263 cyclopentamine Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- COAPWPLCJMVVNS-UHFFFAOYSA-N 1-(1h-1,2,4-triazol-5-yl)piperidine Chemical class C1CCCCN1C1=NC=NN1 COAPWPLCJMVVNS-UHFFFAOYSA-N 0.000 description 6
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 5
- PGNUAHVVDPQCPZ-UHFFFAOYSA-N 5-(3,5-dimethylpyrazol-1-yl)-1h-1,2,4-triazole Chemical compound N1=C(C)C=C(C)N1C1=NC=NN1 PGNUAHVVDPQCPZ-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SXAIXGMQDJUBDK-UHFFFAOYSA-N (2-methylpiperazin-1-yl)-phenylmethanone Chemical compound CC1CNCCN1C(=O)C1=CC=CC=C1 SXAIXGMQDJUBDK-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 description 2
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 2
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 2
- YEQAMPOYHLICPF-UHFFFAOYSA-N 1-piperazin-1-ylpropan-1-one Chemical compound CCC(=O)N1CCNCC1 YEQAMPOYHLICPF-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FAPOQSYMCITJDE-UHFFFAOYSA-N N-cyclohexyl-1H-1,2,4-triazol-5-amine Chemical class C1CCC(CC1)NC1=NNC=N1 FAPOQSYMCITJDE-UHFFFAOYSA-N 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VUNXBQRNMNVUMV-UHFFFAOYSA-N phenyl(piperazin-1-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCNCC1 VUNXBQRNMNVUMV-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Samples | Hela | MCF-7 | Bewo | HL-60 | A549 |
I-1 | 2.22 | 5.58 | nt | 4.84 | 2.15 |
I-2 | 8.35 | 0.98 | 0.82 | 4.66 | nt |
I-3 | 0.58 | 0.77 | nt | 1.45 | 6.60 |
I-4 | 16.61 | 18.10 | 7.11 | 7.83 | nt |
I-5 | 1.48 | 4.75 | 1.76 | 1.88 | nt |
I-6 | 1.47 | 8.08 | 1.51 | 4.22 | nt |
I-7 | 3.88 | 1.65 | 4.02 | 2.43 | nt |
I-8 | 15.11 | 3.44 | 3.25 | 3.64 | nt |
I-9 | 8.31 | 3.89 | 3.59 | 2.66 | nt |
I-10 | 1.29 | 1.91 | 1.86 | 4.93 | nt |
I-11 | 8.57 | 2.60 | 1.82 | 1.45 | nt |
I-12 | 15.11 | 4.43 | 2.59 | 4.24 | nt |
I-13 | 13.20 | 5.15 | 4.64 | 3.02 | nt |
I-14 | 2.91 | 3.55 | 2.57 | 2.70 | nt |
I-15 | 2.30 | 2.64 | 1.67 | 6.99 | nt |
Cisplatin | 0.37 | 7.15 | 8.15 | 8.58 | 2.62 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210563976.0A CN103012410B (zh) | 2012-12-22 | 2012-12-22 | 一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210563976.0A CN103012410B (zh) | 2012-12-22 | 2012-12-22 | 一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012410A true CN103012410A (zh) | 2013-04-03 |
CN103012410B CN103012410B (zh) | 2015-07-01 |
Family
ID=47961562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210563976.0A Active CN103012410B (zh) | 2012-12-22 | 2012-12-22 | 一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012410B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276415A (zh) * | 2018-02-08 | 2018-07-13 | 台州职业技术学院 | 一种烷氧化三唑并四嗪类化合物及其制备方法和应用 |
CN113788835A (zh) * | 2021-10-21 | 2021-12-14 | 台州职业技术学院 | 一种含吗啉和喹啉环的三唑并四嗪类化合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102002008A (zh) * | 2010-10-30 | 2011-04-06 | 台州职业技术学院 | 1-烷基-1,6-二氢-1,2,4,5-四嗪类化合物及其合成方法 |
CN102267983A (zh) * | 2011-06-16 | 2011-12-07 | 台州职业技术学院 | 一种含均四嗪环的均三嗪衍生化合物及其制备方法 |
RU2462466C1 (ru) * | 2011-06-24 | 2012-09-27 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Замещенные азоло[1,2,4,5]тетразины - ингибиторы актинобактериальных серин-треониновых протеинкиназ |
-
2012
- 2012-12-22 CN CN201210563976.0A patent/CN103012410B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102002008A (zh) * | 2010-10-30 | 2011-04-06 | 台州职业技术学院 | 1-烷基-1,6-二氢-1,2,4,5-四嗪类化合物及其合成方法 |
CN102267983A (zh) * | 2011-06-16 | 2011-12-07 | 台州职业技术学院 | 一种含均四嗪环的均三嗪衍生化合物及其制备方法 |
RU2462466C1 (ru) * | 2011-06-24 | 2012-09-27 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Замещенные азоло[1,2,4,5]тетразины - ингибиторы актинобактериальных серин-треониновых протеинкиназ |
Non-Patent Citations (5)
Title |
---|
A.B.SHEREMETEV,等: "Synthesis of [1,2,4]triazolo[4,3-b]-s-tetrazines with incorporated furazan ring", 《RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION》, vol. 61, no. 1, 31 January 2012 (2012-01-31), pages 121 - 130 * |
DAVID E. CHAVEZ,MICHAEL A. HISKEY: "Synthesis of the bi-heterocyclic parent ring system 1,2,4-triazolo[4,3-b][1,2,4,5]tetrazine and some 3,6-disubstituted derivatives", 《J. HETEROCYCLIC. CHEM.》, vol. 35, no. 6, 31 December 1998 (1998-12-31), pages 1329 - 1332 * |
S. G. TOLSHCHINA,等: "Cyclization of (1,2,4,5-tetrazin-3-yl)hydrazones to 3,7-dihydro-1,2,4-triazolo[4,3-b]-1,2,4,5-tetrazines", 《RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION》, vol. 58, no. 6, 30 June 2009 (2009-06-30), pages 1281 - 1290 * |
ZOLTÁN NOVÁK,等: "Synthesis and alkylation of some [1,2,4]triazolo[4,3-b]tetrazines", 《ARKIVOC》, vol. 1, no. 3, 28 August 2000 (2000-08-28), pages 259 - 265 * |
陈辉,等: "新型[1,2,4]三唑[4,3- b]均四嗪类化合物的合成及其抗癌活性", 《合成化学》, vol. 20, no. 4, 31 August 2012 (2012-08-31), pages 475 - 478 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276415A (zh) * | 2018-02-08 | 2018-07-13 | 台州职业技术学院 | 一种烷氧化三唑并四嗪类化合物及其制备方法和应用 |
CN108276415B (zh) * | 2018-02-08 | 2019-07-05 | 台州职业技术学院 | 一种烷氧化三唑并四嗪类化合物及其制备方法和应用 |
CN113788835A (zh) * | 2021-10-21 | 2021-12-14 | 台州职业技术学院 | 一种含吗啉和喹啉环的三唑并四嗪类化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103012410B (zh) | 2015-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10160759B2 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
CN108350006B (zh) | 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途 | |
WO2016110224A1 (zh) | 玻玛西尼的制备方法 | |
CN113603708A (zh) | 一种具有大环骨架结构的新型cdk9抑制剂的制备及其应用 | |
CN110746418A (zh) | 哌柏西利的杂质及其制备方法 | |
CN109053592B (zh) | 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN103012410B (zh) | 一种[1,2,4]三唑[4,3-b]均四嗪衍生化合物及其制备方法 | |
CN102267983B (zh) | 一种含均四嗪环的均三嗪衍生化合物及其制备方法 | |
CN109053594B (zh) | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN107629100B (zh) | 一类包含三氮唑衍生物二核苷酸和肽缀合物及其合成方法 | |
CN112225729B (zh) | 嘧啶类衍生物、其制备方法和应用以及药物组合物 | |
CA3130247C (en) | Fgfr inhibitor compound in solid form and preparation method therefor | |
CN109180583B (zh) | 含杂环砜基及n-氧化物的萘酰亚胺衍生物合成及应用 | |
CN114292270A (zh) | 一种btk抑制剂及其制备方法与应用 | |
CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
CA3143813A1 (en) | Cdk kinase inhibitor | |
CN112194653B (zh) | 一种嘧啶苯并咪唑杂合物、制备方法及抗结肠癌用途 | |
CN110845406B (zh) | 喹啉类化合物的制备方法 | |
CN116621843B (zh) | 一种dna甲基转移酶1抑制剂及其制备方法和用途 | |
CN114621161B (zh) | 一种大黄酸-哌嗪-二硫代氨基甲酸酯杂化物及其制备方法和应用 | |
CN115380024B (zh) | 二氮杂螺吡喃化合物的晶型 | |
CN114787166B (zh) | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 | |
AU2021407012B2 (en) | CRYSTAL FORM OF CASEIN KINASE 1ε INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | |
CN110272388B (zh) | 4-二硫代甲酸哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其合成方法和应用 | |
CN110283163B (zh) | 4-叔丁氧羰基哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130403 Assignee: Taizhou Yongshang Trading Co.,Ltd. Assignor: TAIZHOU VOCATIONAL & TECHNICAL College Contract record no.: X2023980044891 Denomination of invention: A [1,2,4] triazole [4,3-b] tetrazine derivative compound and its preparation method Granted publication date: 20150701 License type: Common License Record date: 20231030 Application publication date: 20130403 Assignee: Taizhou Yier Technology Co.,Ltd. Assignor: TAIZHOU VOCATIONAL & TECHNICAL College Contract record no.: X2023980044675 Denomination of invention: A [1,2,4] triazole [4,3-b] tetrazine derivative compound and its preparation method Granted publication date: 20150701 License type: Common License Record date: 20231027 |
|
EE01 | Entry into force of recordation of patent licensing contract |